Dry Eye
Conditions
Keywords
Eye Dryness, Dry Eye Drink
Brief summary
A study to assess the effect of the Dry Eye Drink on eye dryness
Detailed description
This is a prospective, non-randomized, comparative study of the Dry Eye Drink by Bruder Healthcare that evaluates hydration and subject's assessment on eye dryness. Subjects will administer the Dry Eye Drink by adding one sachet of the Dry Eye Drink powder in 12 Oz of water.
Interventions
DIETARY_SUPPLEMENTDry Eye Drink
Dry Eye Drink is a dietary supplement containing electrolytes, vitamins and natural anti-inflammatories.
Sponsors
CBCC Global Research
Bruder Healthcare
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
OTHER
Masking
NONE
Eligibility
Sex/Gender
ALL
Age
18 Years to 65 Years
Healthy volunteers
No
Inclusion criteria
* Male and/or female subjects aged between 18 and 65 years (both limits inclusive). * Subjects with symptomatic Dry Eye Syndrome confirmed at baseline in at least any one or both the eyes. * Subjects with ≥ 310 mOsmol/L tear osmolarity. * Subjects with ≥ 6 SPEED score. * Subject willing to provide written informed consent and able to comply with protocol requirements.
Exclusion criteria
* Subjects who are pregnant, nursing, or planning a pregnancy within the study participation period. * Have undergone mechanical treatment for meibomian gland dysfunction using thermal pulsation/expression (e.g., LipiFlow) or intense pulsed light (e.g., OptiLight) therapy within 6 months prior to the Screening/Baseline Visit * Have a known hypersensitivity to any of the study product components * Have undergone ocular surgery (e.g., cataract, corneal or refractive surgical procedure) within 6 months prior to the Screening/Baseline Visit * Have evidence of clinically significant ocular trauma * Have active ocular Herpes simplex or Herpes Zoster infection * Have ocular inflammation (uveitis, iritis, scleritis, episcleritis, conjunctivitis or keratitis, with the exception of keratoconjunctivitis sicca) at the discretion of the investigator * Have ocular infection (e.g., viral, bacterial, mycobacterial, protozoan or fungal infection of the cornea, conjunctiva, lacrimal gland, lacrimal sac or eyelids. including hordeolum) * Have severe (Grade 3 or 4) inflammation of the eyelid (e.g., blepharochalasis, staphylococcal blepharitis or seborrheic blepharitis) * Have eyelid abnormalities that significantly affect the lid function (e.g., entropion, ectropion, tumor, edema, blepharospasm, lagophthalmos, severe trichiasis, severe ptosis) * Have an ocular surface abnormality that may compromise the corneal integrity (e.g., prior chemical burn, recurrent corneal erosion, corneal dystrophy, or the effect of any other ophthalmic medication that might in the opinion of the investigator compromise the ocular surface integrity) * Have a systemic condition or disease not stabilized or judged by the Investigator to be incompatible with participation in the study or with the lengthier assessments required by the study (e.g., current systemic infection, uncontrolled autoimmune disease, uncontrolled immunodeficiency disease, history of myocardial infarction or heart disease, etc.) * Participation in any clinical study within 30 days before the first administration of study product. * Subjects who are illiterate and cannot complete the subject diary independently.
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Change on the SPEED score | Day 0 and Day 30 | Change on the subjects' perception of eye dryness from Baseline to end of treatment as assessed by Standard Patient Evaluation of Eye Dryness (SPEED) score |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Change in Tear Osmolarity | Day 0 and Day 30 | Change in Tear Osmolarity from Baseline to end of treatment |
| Change in MMP-9 levels | Day 0 and Day 30 | Change in MMP-9 levels from Baseline to end of treatment |
Countries
United States
Outcome results
None listed